STING1 and neoplasm: Apart from these mechanistic interpretations of the joint action of STING agonist and CAR T cell therapy, the preclinical effects of this combined use, integrating nanotechnology for solid tumor control, were reported by Stephan and colleagues.[107] The authors designed and constructed a microporous scaffold to enable efficient localized delivery of tumor‐targeting T cells and the STING agonist c‐di‐GMP.